Merck has announced the acquisition of all outstanding shares of EyeBio, making it a wholly-owned subsidiary, according to a company press release.
“The EyeBio acquisition further diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases,” Dean Y. Li, MD, PhD, president of Merck Research Laboratories, said in the release. “We are excited to welcome the EyeBio team and look forward to working together to advance Restoret for the patients that need it.”
According to the